Drug intelligence / Profile preview

Rotigotine extended-release microspheres

Development stage: Phase 1
Lead developer: Luye Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

LY03003 is a formulation of rotigotine delivered through weekly intramuscular injection. It is designed to improve symptoms throughout the day and quality of life for patients with Parkinson's disease. The stable release of the drug can improve both motor and non-motor symptoms in patients with early and advanced Parkinson's disease and reduce their "on-off" phenomenon and motor complications. The long-term application of the drug is expected to delay the development of motor complications.

Other names: Rotigotine microspheres

Targets

DRD5 (Dopamine D5 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD2 (Dopamine D2 Receptor)DRD1 (Dopamine D1 Receptor)

Beyond the preview

Go deeper on Rotigotine extended-release microspheres.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rotigotine extended-release microspheres.

Explore the full profile